Southwest Synthetic Pharmaceutical To Consolidate Founder Group’s Pharmaceutical Business
This article was originally published in PharmAsia News
Executive Summary
Southwest Synthetic Pharmaceutical has announced plans to issue additional shares to Peking University International Hospital to acquire the latter's subsidiary Chongqing Daxin Pharmaceutical. Southwest Synthetic and Peking University International Hospital are both subsidiaries of China's IT giant Founder Group. Sources disclose that the conglomerate will transfer its 87.65 percent stake in Daxin Pharmaceutical to Southwest Synthetic, such that all of its pharmaceutical assets are consolidated within one entity. Founder's strategy is to develop IT, pharmaceutical and health care as its main core businesses. (Click here for more - Chinese Language)